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Background: Antiplatelet therapy is central to the secondary prevention of ischemic stroke. Non-response to antiplatelet therapy has been 
associated with worse clinical outcomes. Optimizing antiplatelet therapy based on platelet function testing remains controversial. This study sought 
to determine the clinical outcomes associated with platelet-function guided adjustments in antiplatelet therapy in patients with ischemic stroke or 
transient ischemic attack (TIA). 
Methods: From 1/2005 to 8/2007, 345 patients with ischemic stroke (n = 268) or TIA (n = 77) underwent platelet function testing using optical 
platelet aggregometry. Aspirin non-response was defined as a mean platelet aggregation > 20% with 0.5 mg/ml arachidonic acid or > 70% with 5 
μM adenosine diphosphate (ADP). Clopidogrel non-response was defined as a mean platelet aggregation > 40% with 5 μM ADP. Antiplatelet therapy 
adjustment was defined as any change occurring immediately after testing. Clinical outcomes [death, ischemic stroke, myocardial infarction, TIA, 
thromboembolic event, or bleeding events] were compared between patients with and without platelet-function guided adjustments in antiplatelet 
therapy using univariate and propensity score adjusted analyses. 
Results: In patients presenting with ischemic stroke or TIA, 42% (n = 132) and 33% (n = 56) were non-responders to aspirin and clopidogrel, 
respectively. Mean follow-up time was 4.6 ± 1.1 years. After platelet-function testing, 28% of patients (n=95) had an increase (22%) or decrease 
(6%) in antiplatelet therapy. After propensity score adjustment, an antiplatelet therapy adjustment was associated with significantly increased rates 
of death, ischemic events, or bleeding (HR 1.84, 95% CI 1.16-2.93; p = 0.01) compared with no adjustment in antiplatelet therapy.
Conclusions: Platelet-function guided adjustment in antiplatelet therapy following an ischemic stroke or TIA was associated with significantly 
higher rates of adverse clinical outcomes at late follow up.
